Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer (NYSE: PFE) will host a conference call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025 to provide its full-year 2026 financial guidance. The live webcast will be available at www.pfizer.com/investors, with registration open beginning December 1, 2025. Dial-in is available at 800-456-4352 (U.S./Canada) or 785-424-1086 (international) using passcode 71848. A transcript and replay will be posted on the investor site within 24 hours and remain accessible for at least 90 days.
Pfizer (NYSE: PFE) announced that the U.S. FDA approved PADCEV plus Keytruda as a perioperative (neoadjuvant then adjuvant) treatment for adult cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) on November 21, 2025.
Approval was based on Phase 3 EV-303 (KEYNOTE-905) data showing 60% lower risk of recurrence/progression/death (EFS HR=0.40; p<0.0001) and a 50% lower risk of death (OS HR=0.50; p=0.0002) versus surgery alone; median EFS and OS are not reached for the combination. Grade ≥3 adverse events occurred in 71.3% of combination patients versus 45.9% for surgery alone.
Pfizer (NYSE: PFE) completed its acquisition of Metsera on November 13, 2025, buying all outstanding Metsera shares for $65.60 per share in cash and an enterprise value of approximately $7.0 billion.
The deal includes a contingent value right (CVR) of up to $20.65 per share tied to three clinical and regulatory milestones. Metsera is now a Pfizer subsidiary and its common stock will cease trading on NASDAQ. Key assets transferred include MET-097i (weekly/monthly GLP-1 RA entering Phase 3), MET-233i (monthly amylin analog in Phase 1), an oral GLP-1 RA in Phase 1, and preclinical hormone therapeutics.
Pfizer expects the transaction to be dilutive through 2030 and will update financial outlook with 2026 guidance later this year.
Pfizer (NYSE: PFE) will webcast a discussion with Dave Denton, CFO, at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 a.m. GMT.
Investors and the public can register and access the live webcast at www.pfizer.com/investors. A transcript and replay will be posted within 24 hours after the live event and will remain available for at least 90 days. Registration information is available beginning today on the investor website.
The webcast may include forward-looking statements; risk factors are available in Pfizer's Form 10-K for the year ended December 31, 2024 and subsequent SEC reports.
Summary not available.
Pfizer (NYSE: PFE) reported Q3 2025 revenues of $16.7B and raised and narrowed full-year 2025 adjusted diluted EPS guidance to $3.00–$3.15 while reaffirming revenue guidance of $61.0–$64.0B. Q3 adjusted diluted EPS was $0.87 and reported diluted EPS was $0.62. The company delivered ~$7.2B anticipated net cost-savings target by end of 2027 trajectory and invested $7.2B in internal R&D in the first nine months. The quarter saw operational growth in key brands (Eliquis +22% operationally) while COVID products declined.
Summary not available.
Summary not available.
Pfizer (NYSE: PFE) announced on October 31, 2025 that the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Act for Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR).
The early termination satisfies the HSR Act regulatory review requirements for the proposed acquisition, which had a waiting-period expiry date of November 7, 2025. The transaction remains pending other closing conditions.
Summary not available.